Key terms
About BCYC
Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BCYC news
Feb 28
8:05am ET
Corbus Pharmaceuticals appoints Smethurst as CMO
Feb 22
12:20am ET
Analysts Are Bullish on These Healthcare Stocks: Edgewise Therapeutics (EWTX), Bicycle Therapeutics (BCYC)
Feb 21
8:20am ET
Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC) and Teladoc (TDOC)
Feb 21
8:09am ET
Bicycle Therapeutics: A Strong Buy on Promising Trials and Financial Stability
Feb 21
6:50am ET
Analysts Are Bullish on These Healthcare Stocks: Bicycle Therapeutics (BCYC), Tactile Systems Technology (TCMD)
Feb 21
6:08am ET
Bicycle Therapeutics price target lowered to $55 from $57 at H.C. Wainwright
Feb 21
5:40am ET
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO) and Bicycle Therapeutics (BCYC)
Feb 21
1:15am ET
Bicycle Therapeutics (BCYC) Receives a Buy from JMP Securities
Feb 21
1:11am ET
Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC), GeneDx Holdings (WGS) and Halozyme (HALO)
Feb 21
1:00am ET
Bicycle Therapeutics Is Worried About This – Should You Be Worried Too?
Feb 20
9:50am ET
Analysts Conflicted on These Healthcare Names: Bicycle Therapeutics (BCYC) and 60 Degrees Pharmaceuticals, Inc. (SXTP)
Feb 20
7:23am ET
Bicycle Therapeutics Welcomes Stephen Sands to Board
Feb 20
7:18am ET
Bicycle Therapeutics reports Q4 EPS ($1.16), consensus ($1.23)
Feb 16
11:22am ET
Biotech Alert: Searches spiking for these stocks today
Feb 15
11:05am ET
Biotech Alert: Searches spiking for these stocks today
Dec 20
6:22am ET
Bicycle Therapeutics price target lowered to $32 from $44 at JMP Securities
Dec 20
12:26am ET
Bicycle Therapeutics: A Strong Buy on Innovative Platform and Promising Clinical Trials
Dec 19
7:21am ET
Bicycle Therapeutics price target lowered to $30 from $40 at Morgan Stanley
Dec 19
2:42am ET
Analysts Offer Insights on Healthcare Companies: Rain Therapeutics (RAIN), Reneo Pharmaceuticals (RPHM) and Bicycle Therapeutics (BCYC)
Dec 15
10:45am ET
Buy Rating for Bicycle Therapeutics: BT8009’s Favorable Safety and Promising Efficacy in Urothelial Cancer Treatment
Dec 15
10:41am ET
Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC) and Alnylam Pharma (ALNY)
Dec 15
8:54am ET
Bicycle Therapeutics price target lowered to $43 from $46 at Needham
Dec 15
8:54am ET
Bicycle Therapeutics price target lowered by $3 at Needham, here’s why
Dec 15
8:48am ET
Promising Clinical Data Underpins Buy Rating for Bicycle Therapeutics
Dec 15
8:11am ET
Analysts’ Top Healthcare Picks: Merit Medical Systems (MMSI), Bicycle Therapeutics (BCYC)
Dec 15
6:55am ET
Bicycle Therapeutics: Maintaining Buy Rating Amidst Promising Clinical Developments and Competitive Lead Asset Prospects
Dec 14
7:25am ET
Bicycle Therapeutics to host research and development day
Dec 14
7:06am ET
Bicycle Therapeutics updates clinical programs at first ‘R&D Day’
Dec 11
8:42am ET
Imunon appoints Sebastien Hazard as CMO
Dec 07
4:24pm ET
Bicycle Therapeutics to host research and development day
Dec 07
7:39am ET
Bicycle Therapeutics (BCYC) Gets a Buy from Oppenheimer
No recent news articles are available for BCYC
No recent press releases are available for BCYC
BCYC Financials
Key terms
Ad Feedback
BCYC Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BCYC Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range